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We have recently found that analog V (BXL-353, a calcitriol
analog) inhibits growth factor (GF)-stimulated human benign
prostate hyperplasia (BPH) cell proliferation by disrupting
signal transduction, reducing Bcl-2 expression, and inducing
apoptosis. We now report that BXL-353 blocks in vitro and in
vivo testosterone (T) activity. BPH cells responded to T and
dihydrotestosterone (DHT) with dose-dependent growth and
reduced apoptosis. Exposure of BPH cells to BXL-353 signif-
icantly antagonized both T- and DHT-induced proliferation
and induced apoptosis, even in the presence of T. To verify
whether BXL-353 reduced prostate growth in vivo, we admin-
istered it orally to either intact or castrated rats, supple-
mented with T enanthate. Nonhypercalcemic doses of BXL-
353 time- and dose-dependently reduced the androgen effect
on ventral prostate weight, similarly to finasteride. Compa-
rable results were obtained after chronic administration of
BXL-353 to intact rats. Clusterin (an atrophy marker) gene
and protein were up-regulated by BXL-353 in rat prostate, and
nuclear fragmentation was widely present. The antiandro-
genic properties of BXL-353 did not interfere with pituitary
and testis function, as assessed by serum determination of rat
LH and T. BXL-353 did not compete for androgen binding to
BPH homogenates and failed to inhibit 5-reductase type 1
and type 2 activities. In conclusion, BXL-353 blocks in vitro
and in vivo androgen-stimulated prostate cell growth, prob-
ably acting downstream from the androgen receptor, without
affecting calcemia or sex hormone secretion. BXL-353 and
other vitamin D3 analogs might thus represent an interesting
class of compounds for treating patients with BPH. (Endocri-
nology 144: 3046–3057, 2003)
THE PROSTATE gland retains the plasticity to respond toandrogenic signaling throughout the entire life span,
reaching maximal volume in the aging man (1). This is es-
sentially the physiological basis for the most common uro-
logical problem of the aging male, benign prostate hyper-
plasia (BPH). Approximately 40–50% of men over 60 yr of
age suffer from symptoms related to BPH, and 25–30% of
them require surgery (2). Androgens and age are considered
the main determinants of prostate enlargement, and blocking
androgen receptor (AR) activity is a straightforward thera-
peutic approach for BPH. Agents that inhibit androgen se-
cretion or activity, such as GnRH agonist or AR antagonists,
are indeed very active in reducing prostate growth (3), but
the hypogonadal symptoms they induce strongly limit their
clinical applicability. Even finasteride (F), a drug that selec-
tively inhibits the 5-reductase type 2 (5R-2)-mediated con-
version of testosterone (T) in dihydrotestosterone (DHT),
shows consistent sexual side-effects, reducing its popularity
in aging men, especially in those with borderline erectile
function (4). In addition, although F decreases the rate of
significant BPH-related events, such as acute urinary reten-
tion, and the need for surgery, its effect on prostate growth
is relatively small, resulting in a 15–25% decrease from base-
line (5). Hence, novel therapeutic approaches for age-related
prostate enlargement, not directly related to a block of AR
signaling, have a high medical need.
Since the pioneering experiments of Cunha and colleagues
(6, 7), prostate growth and differentiation have been pre-
sumed to be stimulated by androgens and to be strongly
influenced by intraprostatic stromal growth factors (GFs).
Indeed, in murine models of AR deficiency, prostatic epi-
thelium development from urogenital sinus depends upon
androgen responsiveness of the stroma, and not the reverse
(7). Interestingly, in organ cultures of neonatal rat ventral
prostates, exogenous administration of keratinocyte GF
(KGF), a stromal derived intraprostatic GF, completely re-
placed the requirement of T for prostate growth and branch-
ing morphogenesis (8). Recent studies indicate that KGF
might also be important for human prostate cell growth
(9–11). IGFs have also been implicated in BPH pathogenesis
(12). Patients with the highest circulating levels of IGF-I have
an elevated risk of BPH (13), and type 1 IGF receptor (IGFR1)
as well as IGF-II are more concentrated in the periurethral
zone, where BPH originates in humans, than in other regions
Abbreviations: AR, Androgen receptor; BPH, benign prostate hyper-
plasia; DHT, dihydrotestosterone; F, finasteride; GAPDH, glyceralde-
hyde-3-phosphate dehydrogenase; GF, growth factor; hfPSMC, human
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of the prostate gland (14). Interestingly, in this study IGF-II
gene and protein expression in the periurethral zone of the
prostate was strongly related to androgen levels.
Because the prostate gland is one of the few tissues re-
taining sensitivity to androgen-stimulated growth in the ag-
ing male, targeting intraprostatic stromal GFs might repre-
sent an attractive option for the medical treatment of BPH.
In previous studies we found that in human stromal BPH cell
cultures, a less hypercalcemic analog of calcitriol, analog V
or BXL-353, completely antagonized KGF receptor (KGFR)-
and IGFR1-mediated mitogenic signaling (11, 15). In the case
of KGFR, we also demonstrated that the effect of BXL-353
was at least partially mediated by a disruption of KGF-
induced receptor autophosphorylation (11, 16). In the
present study, we investigated whether BXL-353 interferes in
vitro and in vivo with androgen-induced prostate growth.
Materials and Methods
Materials
MEM, DMEM/Ham’s F-12 medium (1:1), Ham’s F-12 medium, PBS,
BSA (fraction V), glutamine, antibiotics, collagenase type IV, T, DHT,
cyproterone acetate, NADPH, dithiothreitol, phenylmethylsulfonylfluo-
ride, and a kit for measuring calcemia were purchased from Sigma-
Aldrich Corp. (St. Louis, MO). The protein measurement kit was ob-
tained from Bio-Rad Laboratories, Inc. (Hercules, CA). Fetal bovine
serum was purchased from Unipath (Bedford, UK). The unlabeled syn-
thetic androgen R1881, [3H]R1881, and [3H]testosterone were purchased
from NEN Life Science Products (Boston, MA). Anti-IGFR1 monoclonal
antibody (clone IR-3) and rabbit normal immunoglobulin G (IgG) were
obtained from Oncogene Research Products (Boston, MA). Anti-KGFR
polyclonal antibody was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Monoclonal antirat clusterin antibody (mouse mono-
clonal IgG) specific for -chain was obtained from Upstate Biotechnol-
ogy, Inc. (Lake Placid, NY). The Apop-Tag kit for in situ end labeling
(ISEL) was obtained from Oncor (Gaithersburg, MD). Bicalutamide was
a gift from AstraZeneca (Milan, Italy). CHO 1827 and CHO 1829 were
provided by Serono International (Geneva, Switzerland). Instagel Plus
was purchased from Packard (St. Louis, MO). Finasteride (pure sub-
stance; 17-(N,t-butyl)carbamoyl-4-aza-5-androst-1-en-3-one) was a
gift from Merck Sharp & Dohme Research Laboratories (Rahway, NJ).
The analog 1,25-dihydroxy-16-ene-23-yne D3 (BXL-353) was provided
by BioXell (Milan, Italy). Forward and reverse primers specific for AR
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were ob-
tained from MWG (Biotech, Florence, Italy). Forward and reverse prim-
ers for 5R-1 and 5R-2, In Situ Cell Death Detection Kit POD for
terminal deoxynucleotidyl transferase-mediated deoxy-UTP nick end
labeling (TUNEL), and reagents for Western analysis were obtained
from Roche (Indianapolis, IN). Plasticware for cell cultures was pur-
chased from Falcon (Oxnard, CA). Disposable filtration units for prep-
aration of growth medium were purchased from PBI International (Mi-
lan, Italy). Thin layer chromatography silica plates were obtained from
Merck & Co., Inc. (Darmstadt, Germany). T enanthate was purchased
from Geymonat (Anagni, Italy). The Coat-A-Count Total Testosterone
detection kit was purchased from Medical Systems (Genova Struppa,
Italy). The rat LH (rLH) 125I assay system (RIA) was obtained from
Amersham Pharmacia Biotech (Piscataway, NJ).
BPH cell cultures
After obtaining the informed consent of the patients and the approval
of the local ethical committee, BPH cells were obtained from prostate
tissues derived from five patients who underwent suprapubic ad-
enomectomy for BPH. Patients did not receive any pharmacological
treatment in the 3 months preceding surgery. Cell cultures were pre-
pared and maintained as previously described (11). Cells were used
within the fifth passage.
CHO-1827 and CHO-1829 cells
CHO-1827 (transfected with 5R-1) and CHO-1829 cells (transfected
with 5R-2) (17) were maintained in Ham’s F-12 supplemented with 5%
fetal bovine serum in a fully humidified incubator (95% air/5% CO2)
at 37 C.
Tissue specimens
Rat ventral prostate glands were rapidly excised out, weighed, and
quickly frozen in dry ice. Sections of 14 m were excised out by means
of a cryostat from each specimen. Immunohistochemistry experiments
were performed in contiguous cryosections for direct comparison of
tissue morphology, clusterin expression, and apoptosis localization by
TUNEL. For total RNA extraction and Western blot analysis, rat ventral
prostates were pooled from four to six animals.
Animal protocols
Male Sprague Dawley rats (28 d old) were purchased from Charles
River Laboratories, Inc. (Calco, Lecco, Italy). All animal experimentation
was conducted in accord with accepted standards of human animal care.
Castration was performed via the scrotal route under ketamine/xyla-
zine anesthesia. Three days after castration, rats (five to eight animals per
group) were treated, or not, with T enanthate (30 mg/kg) in one or two
separate weekly sc injections and thereafter according to the different
protocols. In the 1-wk protocol they were treated orally with vehicle
(miglyol 812) or BXL-353 at increasing concentrations (1, 3, 5, 10, and 30
g/kg) for four consecutive administrations. Finasteride (10 mg/kg)
was also administered orally to a subset of T-treated castrated rats
according to the same protocol. In the 2-wk protocol, castrated rats
supplemented with T were treated for 5 d the first week and 4 d the
second week with vehicle (miglyol 812), BXL-353 (3, 5, 10, and 30g/kg),
or F (3, 10, and 30 mg/kg) for a total of nine administrations and killed
1 d later.
In the 1-month protocol, intact adult male Sprague Dawley rats (250
g) were treated orally with vehicle (miglyol 812), BXL-353 (3, 10, and 30
g/kg), or F (10 and 40 mg/kg) 5 d/wk for 5 consecutive wk and for
an additional 2 d the sixth week (total of 27 administrations), unless
otherwise specified. Blood for calcium and hormone measurements was
obtained at the end of each experimental protocol.
Binding assay
Cytosol fractions of BPH fragments were prepared as previously
reported (18, 19). For BPH cell homogenate, BPH cells grown in DMEM/
Ham’s F-12 (1:1; without phenol red) supplemented with 10% stripped
fetal bovine serum were harvested and homogenized as reported by
Granchi and colleagues (19, 20). The binding assay for BPH cell or
fragment preparations was essentially performed as previously reported
(19), (final protein concentrations, 1 and 3.6 mg/ml, respectively). In-
cubations of cytosolic fractions or cell homogenates were carried out
with increasing concentration (0.125, 0.25, 0.5, and 1 nm) of [3H]R1881
(specific activity, 83.5 Ci/mmol) in the absence or presence ([3H]R1881,
1 nm) of increasing concentrations of cold R1881 (1010–106 m), DHT
(1010–106 m), T (1010–106 m), bicalutamide (1010–104 m), and
BXL-353 (1010–104 m), when required by the experimental design. To
prevent R1881 binding to progesterone receptor, 1 m triamcinolone
acetonide was added to each tube. Separation of bound and unbound
ligand was achieved as previously described (19, 20). The protein content
was determined by the method of Bradford (21), using BSA as standard.
RT-PCR
Total RNA was extracted with the RNeasy Mini Kit (Qiagen, Valencia,
CA) from BPH cells, BPH tissue, human fetal penile smooth muscle cells
(hfPSMC; positive controls for AR), and CHO 1827 and CHO 1829
(positive controls for 5R-1 or 5R-2). RNA concentrations were deter-
mined by spectrophotometric analysis at 260 nm. The quality of total
RNA was assessed by performing additional RT-PCR for the GAPDH
gene. The conditions for total RNA (500 ng) RT and amplification, and
specific primers for AR, 5R-1, 5R-2, and GAPDH were reported pre-
viously (19, 20). The contamination of genomic DNA was excluded by
performing 35 cycles of amplification without RT.
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BPH cell proliferation assay
All proliferation tests were performed after 24 h of cell starvation in
phenol red- and serum-free medium containing 0.1% BSA. After star-
vation, cells were incubated in the same medium as before, with or
without specific stimuli. Thereafter, cells were trypsinized, and each
experimental point was derived from counting in the hemocytometer
and then averaging at least six different fields for each well as previously
reported (11). For time-course assays, 2  104 cells were seeded onto
12-well plates in growth medium and treated with increasing concen-
trations (1–100 nm) of T for various times (24–96 h). For cell proliferation
assays, 4 104 cells were seeded as before and incubated with increasing
concentrations of steroids (1012–107 m) for 48 h. Experiments were also
performed using a fixed concentration (10 nm) of steroids 1) with or
without anti-KGFR, anti-IGFR1 antibodies, and IgG (1 g/ml); 2) with
or without fixed (1 or 10 nm) or increasing (1020–107 m) concentrations
of BXL-353; and 3) with or without antiandrogens (F, 1 nm; cyproterone
acetate, 100 nm), for 48 h. In the same experiment each experimental
point was repeated in triplicate or quadruplicate and experiments were
performed at least three times. Cell growth results are expressed as the
number (se) of cells or as the percentage (se) of growth compared
with their relative controls.
ISEL
To evaluate the apoptotic index, ISEL on BPH cells was performed
using Apop-Tag in situ apoptosis detection kit peroxidase following the
manufacturer’s instructions (11). Cells were incubated with T (10 nm),
BXL-353 (10 nm), or an equimolar (10 nm) combination of both. The
percentage of apoptotic cells (the number of stained cells divided by the
total number of cells) was calculated in at least five separate fields per
slide in five different slides. Results are expressed as the mean  sem
in three separate experiments.
5R inhibition test
The 5R inhibition assay was performed with CHO cells transfected
with 5R-1 (CHO 1827) or 5R-2 (CHO 1829) according to reported
procedures (22). BXL-353 was added in a concentration range from
109–105 m, using F as a control inhibitor in each experiment.
Northern hybridization analysis
Total RNA was extracted using RNAFast from Molecular Systems
(San Diego, CA). Blotting, labeling, hybridization conditions, and
probes (rat clusterin, 1.5-kb full-length cDNA; GAPDH, 1.2-kb full-
length cDNA) were performed according to previously reported pro-
cedures (23, 24). Quantitation of the autoradiograms was obtained by
densitometric scanning using an Ultrascan XL densitometer (LKB,
Rockville, MD).
Western blot analysis
Prostates were quickly removed, and tissue was homogenized in TTX
buffer [20 mm Tris-HCl (pH 8.0), 100 mm NaCl, 0.2% Triton X-100, 50
g/ml deoxyribonuclease, and 50 g/ml ribonuclease] with Complete
protease inhibitor according to the manufacturer’s instructions (Roche).
Fifty micrograms of total protein extract were run on 10% polyacryl-
amide gel. After protein transfer onto Hybond enhanced chemilumi-
nescence nitrocellulose membranes (Amersham Pharmacia Biotech, Pis-
cataway, NJ), the filters were blocked for 1 h at room temperature in 1%
blocking agent and incubated using monoclonal antihuman clusterin
antibodies in 0.5% blocking agent. After several washes in Tris-buffered
saline/0.05% Tween, membranes were incubated with horseradish
peroxidase-conjugated antimouse IgG antibody for 1 h at room tem-
perature. Clusterin-immunoreactive bands were detected with the
Lumi-Light Plus Western blotting substrate (POD, Roche).
Immunohistochemistry
The entire experimental procedure was performed at room temper-
ature as previously described (25). All cryosections obtained from con-
trols and treated animals were processed in parallel under identical
reaction conditions. For every experimental condition, three alternate
sections from three different rat prostates were examined. Negative
controls, made by excluding the specific antibody from the reaction,
showed no specific staining. Counterstaining was performed with he-
matoxylin, and coverslips were mounted with Eukitt (O. Kindler GmbH
& Co., Germany). Digital high magnification color images were acquired
by means of a CCD camera (Diagnostic Instruments, Chicago, IL)
through the microscope.
TUNEL
DNA fragmentation in prostate cryosections, assessed by means of
TUNEL, was performed using the In Situ Cell Death Detection Kit (POD,
Roche) as recommended by the manufacturer. TUNEL-positive apo-
ptotic nuclei were documented by digital high magnification color im-
ages acquired by CCD camera through the microscope. Counterstaining
was performed with eosin, and coverslips were mounted with Eukitt (O.
Kindler GmbH, Freiburg, Germany).
T and rLH measurements
Serum levels of T and rLH hormones were determined using com-
mercially available RIA kits (specified in Materials and Methods), accord-
ing to the manufacturer’s instructions. To measure serum T in rats,
samples were first added to 4 vol diethyl ether, mixed by gentle inver-
sion for 15 min, and then centrifuged for 5 min at 2000 rpm. The aqueous
phase was frozen in dry ice, and the organic phase was recovered and
evaporated to dryness under a nitrogen stream. The dried extract was
reconstituted in the assay buffer as follows: 1:1 (vol/vol) in intact rats
and 4:1 (vol/vol) in castrated rats.
Calcium measurements
Serum calcium levels were measured with a commercially available
colorimetric assay (Sigma-Aldrich Corp.), according to the manufactur-
er’s instructions.
Statistical analysis
Statistical analysis was performed by one-way ANOVA and paired
or unpaired t tests where appropriate. Binding data were analyzed using
the computerized program LIGAND (26).
The computer program ALLFIT (27) was used for analysis of sigmoid
dose-response curves to obtain estimates of IC50 and EC50 as well as
maximal inhibitory (Imax) and stimulatory (Emax) effects. Data were
expressed as the mean (se).
Results
In vitro effects of androgens, antiandrogens, and BXL-353
on BPH cells
BPH cells express all genes and proteins related to full
androgen sensitivity. In particular, they express specific tran-
scripts for the AR gene and bind with high affinity (Kd 72
34 pm; n  3), and low capacity (2.64  0.5 fm; n  3) to the
synthetic androgen R1881. The receptor density in BPH cells
is similar to that we previously observed in hfPSMC (19), a
classic androgen target. BPH cells also express transcripts for
both subtypes of 5R enzymes, of the same sizes as in
hfPSMC and in CHO cells transfected with type 1 or type 2
5R genes (not shown).
Figure 1A shows that different concentrations of T (1–100
nm) induced a time- and dose-dependent stimulation of BPH
cell growth (n  3). After a 48-h stimulation, the effect of T
was comparable to that induced by its 5-reduced metabo-
lite, DHT (Fig. 1A, inset, n  3). This was confirmed by the
simultaneous fitting, using the program ALLFIT (27), of the
growth curves induced by 48-h stimulation with different
concentrations of the two androgens that showed no statis-
tically significant difference in either 50% effective concen-
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tration (0.38  0.2 nm) or maximum effective concentration
(150  13.8%). T-induced proliferation is at least partially
mediated by autocrine growth factors (Fig. 1B). We previ-
ously observed that the specific blocking antibodies anti-
KGFR and anti-IGFR1 abolished the KGF and des(1–3)-IGF-I
(IGF-I analog that does not bind to IGF-binding proteins)
mitogenic signaling in BPH cells (15). The same anti-KGFR
and anti-IGFR1 antibodies, but not unrelated Igs, signifi-
cantly blunted T-induced cell proliferation, suggesting the
involvement of GFs in mediating T-dependent growth (Fig.
1B; n  4).
The vitamin D3 analog BXL-353 also blocked T-induced
BPH cell proliferation (Fig. 2). BXL-353, at subfemtomolar
concentrations [50% inhibitory concentration (IC50), 0.22 
0.14 fm] abrogated the growth stimulatory effect of T and at
higher concentrations induced a significant decrease in pro-
liferation (maximum inhibitory concentration, 65.8  4.4%)
even when compared with untreated control cells (Fig. 2A;
n  3). This effect was at least in part due to activation of a
death program in BPH cells (Fig. 2B; n  3). The percentage
of apoptotic nuclei detected by ISEL dramatically increased
after a 48-h exposure to 10 nm BXL-353, affecting more than
half of the total cell population. Conversely, treatment with
T significantly reduced the number of BPH cells committed
to death. The simultaneous incubation of T (10 nm) and
BXL-353 (10 nm) partially decreased BXL-353-induced apo-
ptosis; however, more than 40% of cell nuclei still showed
fragmentation (n 3). Thus, BXL-353 blocked the mitogenic
and antiapoptotic properties of T in BPH cells. Figure 3
shows a comparison between the antiandrogenic activity of
BXL-353 (1 nm) and that of well-characterized antiandrogen
compounds, such as the 5R inhibitor F (1 nm) or the AR
antagonist cyproterone acetate (100 nm), on T- and DHT-
stimulated (10 nm) BPH cell growth. As expected, although
cyproterone acetate completely counteracted the prolifera-
tive activity of both T and DHT, F was effective only against
T. In contrast to F, BXL-353 completely blocked both T- and
DHT-stimulated BPH cell growth and again significantly
reduced cell proliferation even when compared with un-
treated cells (n  3).
FIG. 1. Effect of androgens on BPH cell
growth. A, Time course (24–96 h) of BPH
cell proliferation in the absence (control;
f) or presence of different doses of T (E,
1 nM; ‚, 10 nM; , 100 nM). Results are
the mean SEM of three separate exper-
iments performed in quadruplicate (*,
P 0.01 vs. control). Inset, Effect of 48-h
incubation with increasing concentra-
tions (1012–107 nM) of T () or DHT
(F) on BPH cell proliferation. Results are
expressed as the percent increase
(mean SEM) over their relative controls
in three different experiments per-
formed in triplicate. °, P  0.05; *, P 
0.01 (vs. control). After ALLFIT interpo-
lation, T and DHT exert a similar mito-
genic effect in BPH cells, with a 50%
effective concentration of 0.38  0.2 nM
and a maximum effective concentration
of 150  13.8%. B, Effects of anti-KGFR
antibody (KGFR Ab; 1 g/ml) and anti-
IGFR1 antibody (IGFR1 Ab; 1 g/ml) or
unrelated immunoglobulins (IgG, 1 g/
ml) on T-stimulated (10 nM) BPH cell
growth. After 24-h starvation, BPH cells
were stimulated with T and antibodies
as indicated for an additional 48 h. Re-
sults are expressed as the percent in-
crease (mean  SEM) over their relative
controls in four different experiments
performed in quadruplicate. *, P  0.01
vs. control; °, P 0.01 vs. T-treated cells.
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In vivo effects of androgens, antiandrogens, and BXL-353
on prostate growth
To verify whether BXL-353 could counteract the T growth
stimulatory effect in in vivo models, we first orally treated
T-replaced castrated rats with increasing concentrations of
this compound or F for different time periods (Fig. 4). As
shown in Fig. 4, A and B, castration dramatically reduced
ventral prostate weight, whereas T enanthate administration
(30 mg/kg) restored it partially (after 1 wk) or completely
(after 2 wk). After 1 wk of T administration (Fig. 4A), BXL-353
dose-dependently reduced T-induced prostate growth, with
a maximal effect (44% inhibition) at 5 g/kg. In this model,
F (10 mg/kg) was ineffective in abrogating androgen stim-
ulation. After 2 wk of T treatment (Fig. 4B), BXL-353 was still
able to significantly reduce T-stimulated rat ventral prostate
growth, with a maximal effect at 30 g/kg (35% inhibition).
This inhibition was comparable to that induced by 3 mg/kg
F, but was lower than the inhibition obtained with higher
doses of F (10 and 40 mg/kg). In intact adult rats (Fig. 4C),
chronic administration (1 month) of both BXL-353 and F
significantly reduced prostate weight. Maximal inhibition
(38%) was obtained with the highest dose of BXL-353 (30
FIG. 2. Effect of BXL-353 on BPH cell
proliferation and apoptosis. A, Effect of
48-h incubation with increasing concen-
trations (1020–107 M) of BXL-353 on
T-stimulated (10 nM) BPH cell prolifer-
ation (IC50  0.22  0.14 fM; maximum
inhibitory concentration, 65.8  4.4%).
Results are expressed as the percent
variation (mean  SEM) over their rel-
ative controls (; see left ordinate axis)
or over the maximal T stimulation [10
nM ( ); see right ordinate axis] in three
different experiments performed in
triplicate. ˆ, P  0.05; *, P  0.01 (vs.
control). °, P 0.01 (vs. T-treated cells).
B, Effects of BXL-353 (10 nM), T (10 nM),
and equimolar concentrations (10 nM) of
T and BXL-353 on DNA fragmentation
on BPH cells as detected by ISEL. The
apoptotic index (percentage) represents
the number of stained nuclei over BPH
cells in each of at least five separate
fields per slide. Results are expressed as
the mean  SEM in three separate ex-
periments. a, P  0.01 (vs. control). b,
P  0.01 (vs. BXL-353-treated cells). c,
P  0.01 (vs. T-treated cells).
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g/kg), an effect comparable to that exerted by high doses
of F. Importantly, in all of the experimental protocols, oral
administration of different doses of BXL-353 did not cause
hypercalcemia (Table 1) or any other discernible toxicity.
BXL-353 up-regulates clusterin gene and protein expression
in rat ventral prostate
Clusterin is a glycoprotein overexpressed in rat ventral
prostate undergoing organ involution and cell atrophy after
different protocols of androgen ablation (23), including F
administration (25). Accordingly, as shown in Fig. 5A, cas-
tration dramatically up-regulated clusterin mRNA abun-
dance in the rat ventral prostate. The effect of orchidectomy
was completely reversed by a 2-wk administration of T.
However, simultaneous treatment with both BXL-353 (30
g/kg) and F (40 mg/kg) partially blunted the effect of T. In
intact rats (Fig. 5B), chronic administration (1 month) of both
BXL-353 (30 g/kg) and F (40 mg/kg) induced a similar
increase in clusterin gene expression. As shown in Fig. 5C,
the effect of BXL-353 on clusterin mRNA abundance in the
ventral prostate of intact rats was time and dose dependent.
It was apparent after the first week of treatment with the
highest dose of BXL-353 (30 g/kg) and was evident after 2
wk with both doses tested (3 and 30 g/kg). In intact rats,
clusterin protein also increased after either 1 or 2 wk of
treatment with 30 g/kg BXL-353 (Fig. 5D).
BXL-353 induces atrophy and apoptosis in rat
ventral prostate
Next we analyzed the effects of BXL-353 on the morphol-
ogy of the ventral prostate from intact and castrated rats (Fig.
6). Clusterin expression, as revealed by immunohistochem-
istry, is reported in the upper panels (Fig. 6, A–F), and nuclear
fragmentation, as detected by TUNEL, is shown in the bottom
panels (Fig. 6, G and H). Figure 6A shows a control section;
in the prostate of intact rats, clusterin labeling was virtually
absent. Orchidectomy induced, after only 4 d, marked atro-
phy of the ventral prostate, characterized by a homogeneous
and intense positivity for clusterin in the flattened epithelial
cells of the gland (Fig. 6B). Figure 6C shows the effect of 2-wk
administration of the lowest dose of BXL-353 (3 g/kg) to
intact rats. Clusterin was expressed in the majority of the
epithelial cells, even in the absence of evident morphological
hallmarks of atrophy. Conversely, after the same length of
exposure, the highest dose of BXL-353 (30 g/kg) induced
diffuse epithelial atrophy and clusterin expression (Fig. 6D).
Figure 6E emphasizes, at a higher magnification, the clus-
terin labeling of the cuboidal atrophic cells of the glandular
epithelium. Figure 6F shows that in T-replaced castrated rats,
BXL-353 administration for 2 wk induced the appearance of
clusterin staining only in the scanty atrophic epithelial cells.
It is interesting to note that apoptosis was clearly evident in
all preparations studied after treatment with BXL-353, as
shown in Fig. 6G (intact rats) or Fig. 6H (T-replaced castrated
rats). Evident nuclear fragmentation was also detected in
stromal cells (Fig. 6G).
BXL-353 does not affect 5R or AR activity
Because we found that BXL-353 and F exerted similar
antiandrogenic effects both in vitro and in vivo, we examined
the possibility that BXL-353 might also effect 5R activity.
Therefore, we tested the ability of BXL-353 and F to inhibit
5R activity in CHO cells transfected with type 1 (Fig. 7A)
and type 2 (Fig. 7B) 5R isoenzymes. Although F inhibited
T conversion into DHT with the expected IC50, BXL-353 did
not affect the activity of both subtypes of 5R up to the
micromolar range (n  3). In addition, to rule out the pos-
sibility that BXL-353 might directly interact with the AR, we
performed binding studies in human BPH homogenates us-
ing [3H]R1881. Figure 7C shows displacement curves ob-
tained in BPH prostate homogenates (n 3). LIGAND anal-
ysis (26) of results from three separate experiments indicated
FIG. 3. Effects of antiandrogens and BXL-353 on androgen-stimulated BPH cell growth. After 24 h starvation, BPH cells were incubated for
48 h with BXL-353 (1 nM) or antiandrogens [F, 1 nM; cyproterone acetate (Cyp), 100 nM] in the presence or absence of T (10 nM) or DHT (10
nM). Results are expressed as the percent variation (mean  SEM) over their relative controls in four different experiments performed in
quadruplicate. *, P  0.01 (vs. control). °, P  0.01 (vs. androgen-treated cells).
Crescioli et al. • Effect of Vitamin D on BPH Endocrinology, July 2003, 144(7):3046–3057 3051
that R1881 (Kd 0.18 0.06 nm), DHT (Kd 0.17 0.08 nm),
T (Kd  1.6  0.86 nm), and the AR antagonist bicalutamide
(Kd 178 84 nm) completely displaced [
3H]R1881 binding.
Conversely, BXL-353 did not compete for [3H]R1881 binding
at any of the concentrations tested (up to 100 m; n  3).
BXL-353 does not change rLH and T serum levels
To investigate whether BXL-353 reduced prostate growth
by interfering with pituitary or testis function, we measured
rLH and T serum levels in castrated or intact rats after treat-
ment with different doses of BXL-353 (3, 10, and 30 g/kg)
or F (10 mg/kg). As shown in Table 2B, castration signifi-
cantly reduced T and increased rLH serum levels. A 2-wk
administration of T enanthate (30 mg/kg) significantly re-
duced rLH concentrations and restored serum T levels to
those observed in control rats. BXL-353 at any dose tested
failed to significantly affect either rLH or T serum levels.
Similarly, chronic administration (1 month) of different
doses of BXL-353 (3, 10, and 30 g/kg) did not modify rLH
and T serum levels in intact rats (Table 2A).
Discussion
Our results show, for the first time, that a vitamin D an-
alog, BXL-353, reduces in vitro and in vivo prostate growth by
decreasing cell proliferation and inducing apoptosis, even in
the presence of T, the most important trophic factor for the
prostate gland.
Vitamin D3 and its active metabolite, calcitriol, are sec-
osteroid hormones modulating calcium homeostasis
through actions on kidney, bone, and the intestinal tract.
Increasing evidence accumulated during the last decade in-
dicates that the prostate gland is also a target of secosteroids.
The human prostate expresses the vitamin D receptor (VDR)
(28), and calcitriol inhibits the in vitro growth of both epi-
thelial (29) and stromal (11) BPH cells. In addition, calcitriol
exhibits antiproliferative and prodifferentiating activities in
malignant prostate cell lines (30–32) and in some in vivo
models of prostate cancer (33, 34). It is presumed that these
effects are essentially due to a double action of calcitriol: a
Go/G1 arrest in the cell cycle progression and an induction
of apoptosis, by increasing, respectively, cyclin-dependent
kinase inhibitors and the ratio of survival factors such as
Bax/Bcl-2 (see Refs. 35 and 36 for reviews). In addition,
recent evidence indicates that calcitriol is able to inhibit an-
giogenic signaling between endothelial and cancer cells (37).
Based on these observations, clinical trials of calcitriol as a
FIG. 4. Effect of BXL-353 or F on rat ventral prostate weight. A,
Castrated rats were supplemented with a single injection of T enan-
thate (30 mg/kgwk) and treated orally for 4 d with vehicle or in-
creasing concentrations of BXL-353 (1–30 g/kg) or F (10 mg/kg).
Ventral prostate weight is expressed as the percent variation (mean
SEM) in weight of T-replaced castrated rats in two separate experi-
ments. Ventral prostate weight in vehicle-treated intact (control) or
castrated rats is also reported. ˆ, P  0.05; *, P  0.01 (vs. T-supple-
mented vehicle-treated rats). °, P  0.01 (vs. T-supplemented F-
treated rats). B, Castrated rats were injected with T enanthate (15
mg/kgwk) and treated orally for 5 d/wk for 2 consecutive wk with
vehicle or increasing concentrations of BXL-353 (3–30 g/kg) or F
(3–40 mg/kg). Ventral prostate weight is expressed as the percent
variation (mean SEM) in weight of T-replaced castrated rats (n 4).
Ventral prostate weight in vehicle-treated intact (control) or castrated
rats is also reported. *, P  0.01 (vs. T-supplemented vehicle-treated
rats). °, P  0.01; ˆ, P  0.05 [vs. T-supplemented BXL-353 (30
g/kg)-treated rats]. C, Intact adult rats were treated orally for more
than 1 month (5 times/wk for a total of 27 administrations) with
vehicle (control) or increasing concentrations of BXL-353 (3–30g/kg)
or F (10 and 40 mg/kg). Ventral prostate weight is expressed as the
percent variation (mean SEM) in weight of control rats (n 4). *, P
0.01 (vs. control rats).
TABLE 1. Calcemia (milligrams per deciliter) in T-replaced
castrated rats after 1 wk of treatment with different doses of
BXL-353
Castrated rats (1 week) Serum calcium
Control 9.72  0.18
BXL-353 (1 g/kg) 9.02  0.27
BXL-353 (3 g/kg) 8.96  0.27
BXL-353 (5 g/kg) 9.76  0.31
BXL-353 (10 g/kg) 8.94  0.26
BXL-353 (30 g/kg) 10.28  0.23
One-week treatment with different doses (1, 3, 5, 10, and 30 g/kg)
of BXL-353 did not change calcium serum levels in castrated rats
replaced with T enanthate (30 mg/kgwk) compared with controls.
Results are the mean  SEM of rats per group [five to eight animals
per group (as specified in Materials and Methods)]. Similar results
were obtained at the other time points or in in intact animals (not
shown).
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treatment for human prostate cancer have been started (38,
39). Although preliminary results were promising, a major
drawback of calcitriol is the dose-limiting effect of hyper-
calcemia and hypercalciuria, which prevents the adminis-
tration of pharmacological doses of the hormone. Therefore,
analogs of calcitriol that retain antiproliferative activity with-
out exhibiting side-effects on calcium metabolism have been
developed. Among these analogs, BXL-353 is one of the most
effective in inhibiting growth and promoting differentiation
in several in vivo (40, 41) and in vitro (16, 42) experimental
models of prostate cancer. In particular, BXL-353 reduced the
proliferation of prostate cancer cell lines and induced apo-
ptosis even in the presence of potent growth factors, such as
KGF (16). BXL-353 was able to reduced KGF-induced Bcl-2
overexpression and cell survival by directly interfering with
KGFR autophosphorylation (16). Hence, we hypothesized a
novel mechanism to explain the antiproliferative effect of
vitamin D analogs in prostate cells: disruption of prostate GF
signaling.
We recently observed that GF signaling was blocked by
BXL-353 not only in malignant prostate cancer cells (16) but
also in nonmalignant prostate cells derived from BPH pa-
tients (11, 15). Therefore, we asked whether BXL-353 might
also antagonize the growth stimulatory properties of the
major GF for normal prostate cells, T. If this is the case,
BXL-353 could be considered as a treatment for human BPH.
For in vitro studies we employed BPH cells, which are not
only positive for the AR gene and protein, but are also re-
sponsive to androgen stimulation with a time- and dose-
dependent growth increase. Moreover, BPH cells express
both subtypes of 5R and are sensitive to F treatment.
In this study, we report that BXL-353, even at subpico-
molar concentrations, completely antagonized T-stimulated
BPH cell growth and, in a rat model, reduced T-induced
ventral prostate growth to an extent comparable to that pro-
duced by F. In addition, like F, BXL-353 blunted the effect of
T on castration-induced clusterin mRNA up-regulation in rat
ventral prostate and induced a time- and dose-dependent
increase in clusterin gene and protein expression in intact
rats, with a concomitant decrease in prostate size. Clusterin
is a ubiquitous sex steroid-down-regulated protein (23, 43,
44) with as yet unknown functions. In the prostate, clusterin
expression is clearly inversely related to progression in the
cell cycle (45, 46) and directly related to gland atrophy (25,
47). Transient overexpression of clusterin induced cell cycle
arrest and decreased DNA synthesis in human prostate ep-
ithelial cells (45). As previously described (47), immunopos-
itivity for clusterin was virtually absent in the normal rat
ventral prostate, whereas a dramatic increase in labeling was
observed soon after orchidectomy or F administration (25).
Similarly, BXL-353 administration strongly increased the
FIG. 5. Effect of BXL-353 and F on clusterin gene and protein ex-
pression in the rat ventral prostate. A, Northern analysis of clusterin
mRNA expression in the ventral prostate of vehicle-treated intact
(lane 1) or castrated (lane 2) rats. Lanes 3–5, Clusterin gene expres-
sion in orchidectomized rats supplemented for 2 wk with T enanthate
(30 mg/kg) and orally treated with vehicle (lane 3), BXL-353 (30g/kg;
lane 4), or F (40 mg/kg; lane 5). Every lane was loaded with 10g total
RNA. The corresponding GAPDH expression and ethidium bromide
staining of the gel are shown below the blot. The blot is representative
of two separate experiments. B, Northern analysis of clusterin mRNA
expression in the ventral prostate of adult intact rats treated orally
for more than 1 month (5 times/wk, 27 administrations) with vehicle
(lane 1), BXL-353 (30g/kg; lane 2), or F (40 mg/kg; lane 3). Every lane
was loaded with 10 g total RNA. The corresponding GAPDH ex-
pression and the ethidium bromide staining of the gel are shown below
the blot. The blot is representative of two separate experiments. C,
Northern analysis of clusterin mRNA expression in the ventral pros-
tate of intact adult rats orally treated for 1 wk (4 administrations)
with vehicle (lane 1) or different doses of BXL-353 (3 and 30 g/kg;
lanes 2 and 4, respectively). Effect of 2-wk oral treatment (9 admin-
istrations) of different doses of BXL-353 (lane 3, 3 g/kg; lane 5, 30
g/kg) is also shown. Every lane was loaded with 10g total RNA. The
corresponding GAPDH expression and the ethidium bromide staining
of the gel are shown below the blot. The blot is representative of two
separate experiments. D, Western blot detection of clusterin protein
in the ventral prostate of adult intact rats treated for 1 wk with vehicle
(lane 1) or BXL-353 (30 g/kg; lane 2). Results after 2-wk treatment
(9 administration) with BXL-353 (30 g/kg) are shown in lane 3. All
lysates were obtained as described in Materials and Methods, and 30
g proteins were separated by 10% SDS-PAGE, transferred onto
nitrocellulose membrane, and probed for clusterin expression with
antirat clusterin polyclonal antibody (1:100). Molecular mass mark-
ers (kilodaltons) are indicated to the right of the blot. The blot is
representative of two separate experiments.
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FIG. 6. Morphological effects of BXL-353 on rat ventral prostate. A–F, Representative fields obtained from cross-sections (14 m) of whole
prostate glands immunostained with a monoclonal antibody against rat clusterin and counterstained with hematoxylin. In vehicle-treated intact
adult rats, clusterin labeling is barely detectable in the cytoplasm of a few epithelial cells (A; magnification, 10). After orchidectomy (B;
magnification, 10), almost all of the cuboidal atrophic epithelial cells were intensively stained. Some stromal cells were also labeled. After
2-wk (nine administrations) treatment of intact rats with the lowest dose of BXL-353 (3 g/kg), almost all of the columnar epithelial cells of
the glands were positive for clusterin (C; magnification,10), without evident morphological hallmarks of atrophy. Conversely, the highest dose
of BXL-353 (30 g/kg) induced both epithelial gland atrophy and clusterin expression (D; magnification, 10). E, Higher magnification (20)
of results obtained under the same experimental conditions as those in D. The arrow indicates typical atrophic cuboidal cells of the glandular
epithelium with an evident clusterin staining. F, Typical results obtained in the ventral prostate of castrated and T-supplemented rats after
2-wk treatment (nine administrations) with BXL-353 (30 g/kg). In T-treated glands, BXL-353 administration induced scanty foci of atrophy
and clusterin staining (arrow). G and H, DNA fragmentation in rat prostate cryosections as assessed by TdT-mediated deoxy-UTP nick
end-labeling (TUNEL). Two-week treatment (nine administrations) of intact (G; magnification, 10) or T-treated castrated rats (H; magni-
fication, 10) with BXL-353 (30 g/kg)-induced apoptosis in the majority of epithelial and stromal cells.
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number of clusterin-positive cells, in parallel with enhanced
morphological evidence of glandular atrophy. BXL-353 was
also able to increase the number of prostate cell doomed to
die. Indeed, in both BPH cells and rat prostate, BXL-353
induced a massive increase in DNA fragmentation, as de-
tected by ISEL and TUNEL, respectively. Similar results were
previously reported in rat ventral prostate after treatment
with F (48). However, at variance with F, BXL-353 did not
affect 5R-1 or 5R-2 activity in CHO cells transfected with
either 5R isoenzyme subtype. Furthermore, the antiprolif-
erative effect of BXL-353 in BPH cells was evident not only
in T-stimulated, but also in DHT-stimulated, cells, as ob-
served with the AR antagonist cyproterone acetate. How-
ever, BXL-353 does not bind to the human AR. Hence, al-
though BXL-353 behaves as an antiandrogen, it does not
interfere directly with the AR. Interestingly, BXL-353 admin-
istration to either castrated or intact rats does not affect
pituitary and gonadal release of rLH and T. In addition,
previous studies have indicated that VDR ligation up-
regulates, rather than represses, the AR gene and protein
expression (49, 50). It is therefore possible that BXL-353 coun-
teracts the mitogenic action of androgens in the prostate by
acting downstream from the AR. One possible target for
BXL-353 is androgen-dependent intraprostatic GF signaling.
We have previously demonstrated that both KGFR and
IGFR1 activities are involved in BPH cell proliferation (9, 11,
15). Antibodies against both types of receptors not only com-
FIG. 7. Lack of antiandrogenic properties by BXL-353. A and B, In-
hibition curves toward 5R activity in CHO 1827 and CHO 1829,
stably transfected with type 1 (A) or type 2 (B) isoenzymes, respec-
tively, were measured in the presence of increasing concentration
(1010–105 M) of BXL-353 (F) or F (f). While F inhibits 5R activity
with the expected IC50 (type 1 isoenzyme: IC50  0.9  0.2 M; type
2 isoenzyme: IC50  35  5 nM), BXL-353 did not interfere with the
conversion up to the micromolar range (type 1 isoenzyme: IC50 
10.2 0.29 M; type 2 isoenzyme: IC50 10 M). Similar results were
obtained in two other separate experiments. C, Effects of increasing
concentrations of BXL-353 and several AR ligands on [3H]R1881
binding to human prostate homogenates. Cytosol preparations (n 
3) of human prostate (obtained at surgery from patients affected by
BPH) were incubated in the presence of [3H]R1881 and increasing
concentrations of the corresponding unlabeled ligand (X), DHT (), T
(), bicalutamide (), and BXL-353 (‚). Although all of the AR li-
gands displaced [3H]R1881 binding as expected (R1881: Kd  0.18 
0.06 nM; DHT: Kd  0.17  0.08 nM; T: Kd  1.6  0.86 nM; bicalu-
tamide: Kd  178  84 nM), BXL-353 did not compete at any of the
concentrations tested (up to 100 M).
TABLE 2. rLH (nanograms per milliliter) and T (nanomolar
concentrations) serum levels in intact or T-replaced castrated rats
after treatment with different doses of BXL-353
rLH T
A. Intact rats
Control 3.16  0.51 7.20  1.95
F 2.85  0.30 8.55  1.26
BXL-353 (3 g/kg) 3.46  0.27 8.18  1.82
BXL-353 (10 g/kg) 4.2  0.13 7.67  1.77
BXL-353 (30 g/kg) 2.92  0.2 6.92  1.67
B. Castrated rats
Control 3.74  0.61 4.4  0.54
Castrated 25.18  3.76a 1.65  0.12a
T-replaced 7.2  2.23 3.02  0.56
F 4.44  1.14 4.61  0.74
BXL-353 (3 g/kg) 5.52  1.86 5.38  1.33
BXL-353 (10 g/kg) 6.28  1.40 2.98  0.47
BXL-353 (30 g/kg) 5.88  2.11 3.92  0.30
A, Chronic administration (1 month) of F (40 mg/kg) or BXL-353
(3, 10, and 30 g/kg) did not change rLH and T serum levels in intact
rats. B, In castrated rats serum T is significantly reduced, whereas
serum rLH significantly increased (a, P 0.01 vs. control). After 2-wk
treatment with T enanthate (30 mg/kgwk) rLH concentrations were
significantly reduced, and T serum levels were restored as in control
rats. BXL-353 at all doses tested did not significantly affect either rLH
or T serum levels.
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pletely abrogated the mitogenic effect of their specific agonist
(15), but also blunted the proliferative activity of T, as shown
in the present study. Hence, it is possible that BXL-353 also
interferes with the androgen activity on prostate growth by
disrupting intraprostatic GF signaling (11, 15, 16). An expla-
nation for the present and previous findings is that the VDR,
via an extranuclear/nongenomic effect, is functionally cou-
pled to one or more phosphatase activities, and that VDR
interaction with its ligand promotes a series of protein kinase
dephosphorylations. Indeed, calcitriol and its analogs in-
duced a prompt decrease not only in phosphorylated KGFR
(11, 16), but also in phospho-Erk and phospho-Akt (51, 52).
Consistent with this hypothesis, recent evidence (51) indi-
cates that the VDR, upon ligand binding, physically interacts
with the catalytic subunit of some protein phosphatases, such
as PP1 and PP2Ac, promoting their enzymatic activities. This
implies, for instance, the consequent inactivation of p70S6k,
a kinase essential in the G0/G1 transition (53). The activated
AR is also a multiple phosphorylated protein, and some of
its phosphorylation sites (such as Ser650) are required for full
transcriptional activity (see Ref. 54 for review). Hence, it is
possible that calcitriol (and some of its analogs) might acti-
vate the catalytic subunit of distinct families of phosphatases,
exerting antiproliferative effects on AR-GF signaling or tran-
scriptional activities. This hypothesis might explain why
BXL-353, but not the other antiandrogens tested, also re-
duced the growth of untreated BPH cells and induced ap-
optosis (and Bcl-2 down-regulation) even in the absence of
GF (11, 15, 16) or T itself (present study).
In conclusion, BXL-353, at nonhypercalcemic doses, coun-
teracts in normal prostate cells AR-induced proliferation and
under several experimental conditions is comparable to F.
Hence, its clinical use to reduce prostate size might be pos-
tulated. Because BXL-353 does not bind to the AR nor does
it interfere with DHT formation, it should not share with
other antiandrogens sexual side-effects, such as decreased
libido, altered sexual potency, or ejaculatory dysfunctions
(55), that may limit the patient compliance for 5R-2 inhib-
itors (4) as well as dual 5R inhibitors, such as dutasteride
(56). Because the prostate gland is one of the few AR targets
retaining the plasticity to respond to T with a rather contin-
ued proliferation throughout the entire life span (1), the
antiandrogenic activity of BXL-353 could be limited to the
inhibition of prostate gland growth. The present results in-
dicate that BXL-353 or other well-tolerated calcitriol analogs
might therefore represent a new class of drugs beneficial
for the most common urological problem of the aging
male, BPH.
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